The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo

Zhou,Jihao; Li,Yonghui; Yao,Yushi; Wang,Lixin; Gao,Li; Gao,Xiaoning; Luo,Xufeng; Li,Jingxin; Jiang,Mengmeng; Zhou,Minhang; Wang,Lili; Yu,Li

doi:10.3892/mmr.2013.1659

The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo

Authors:
- Jihao Zhou
- Yonghui Li
- Yushi Yao
- Lixin Wang
- Li Gao
- Xiaoning Gao
- Xufeng Luo
- Jingxin Li
- Mengmeng Jiang
- Minhang Zhou
- Lili Wang
- Li Yu
View Affiliations

Affiliations: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: August 28, 2013 https://doi.org/10.3892/mmr.2013.1659
Pages: 1549-1555

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer‑testis antigens (CTAs) are a group of tumor‑associated antigens restricted to male germ cells under normal physiological conditions. CTAs are expressed in certain types of tumors and thus are a novel target for immunotherapy. Nuclear RNA export factor 2 (NXF2) is a CTA of which the expression pattern, regulation and clinical significance are unclear. In the present study, following treatment with a demethylating agent, decitabine, NXF2 expression was detected in the majority of the NXF2‑negative acute leukemia cell lines, but not in healthy donor samples. This finding was confirmed by western blot analysis. Eight primary acute leukemia bone marrow samples were treated with decitabine in vitro, and results showed that NXF2 expression was significantly upregulated. In another nine acute myeloid leukemia or myelodysplastic syndrome patients, it was noted that the expression of NXF2 was upregulated in all patients following the first cycle of decitabine, which suggested that NXF2 was activated by decitabine treatment in vivo. Furthermore, NXF2 expression in acute leukemia cells was demonstrated to be regulated by CpG island hypermethylation. To the best of our knowledge, this is the first study to demonstrate that NXF2 is activated by demethylation in acute leukemia cells in vitro and in vivo. NXF2 may therefore serve as a novel target for immunotherapy against acute leukemia.

View Figures

View References

1	Fratta E, Coral S, Covre A, et al: The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 5:164–182. 2011. View Article : Google Scholar : PubMed/NCBI
2	van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991.
3	Weber J, Salgaller M, Samid D, et al: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 54:1766–1771. 1994.PubMed/NCBI
4	De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F and Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA. 93:7149–7153. 1996.PubMed/NCBI
5	van Baren N, Chambost H, Ferrant A, et al: PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol. 102:1376–1379. 1998.PubMed/NCBI
6	Chen YT, Boyer AD, Viars CS, Tsang S, Old LJ and Arden KC: Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet. 79:237–240. 1997. View Article : Google Scholar : PubMed/NCBI
7	Gure AO, Türeci O, Sahin U, et al: SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer. 72:965–971. 1997. View Article : Google Scholar : PubMed/NCBI
8	Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, et al: The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 34:899–905. 2010.
9	Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4⁺ T cells against NY-ESO-1. N Engl J Med. 358:2698–2703. 2008. View Article : Google Scholar : PubMed/NCBI
10	Fradet Y, Picard V, Bergeron A and LaRue H: Cancer-testis antigen expression in bladder cancer. Prog Urol. 15(Suppl 1): 1303–1313. 2005.PubMed/NCBI
11	Calabrò L, Fonsatti E, Altomonte M, et al: Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J Cell Physiol. 202:474–477. 2005.PubMed/NCBI
12	Wang PJ, McCarrey JR, Yang F and Page DC: An abundance of X-linked genes expressed in spermatogonia. Nat Genet. 27:422–426. 2001. View Article : Google Scholar : PubMed/NCBI
13	Takano K, Miki T, Katahira J and Yoneda Y: NXF2 is involved in cytoplasmic mRNA dynamics through interactions with motor proteins. Nucleic Acids Res. 35:2513–2521. 2007. View Article : Google Scholar : PubMed/NCBI
14	Chen CP, Su YN, Lin HH, et al: De novo duplication of Xq22.1→q24 with a disruption of the NXF gene cluster in a mentally retarded woman with short stature and premature ovarian failure. Taiwan J Obstet Gynecol. 50:339–344. 2011.PubMed/NCBI
15	Pan J, Eckardt S, Leu NA, et al: Inactivation of Nxf2 causes defects in male meiosis and age-dependent depletion of spermatogonia. Dev Biol. 330:167–174. 2009. View Article : Google Scholar : PubMed/NCBI
16	Stouffs K, Tournaye H, Van der Elst J, Liebaers I and Lissens W: Is there a role for the nuclear export factor 2 gene in male infertility? Fertil Steril. 90:1787–1791. 2008. View Article : Google Scholar : PubMed/NCBI
17	Chen YT, Ross DS, Chiu R, et al: Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One. 6:e178762011. View Article : Google Scholar : PubMed/NCBI
18	Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM and Pinilla-Ibarz JA: Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res. 15:3406–3415. 2009. View Article : Google Scholar : PubMed/NCBI
19	Jaatinen T and Laine J: Isolation of mononuclear cells from human cord blood by Ficoll-Paque density gradient. Curr Protoc Stem Cell Biol. Chapter 2(Unit 2A.1)2007.PubMed/NCBI
20	Lübbert M, Ruter BH, Claus R, et al: A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 97:393–401. 2012.PubMed/NCBI
21	van Dongen JJ, Macintyre EA, Gabert JA, et al: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 13:1901–1928. 1999.
22	Li CS, Chen C, Zheng P and Liu Y: Transgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis. PLoS One. 5:e134392010. View Article : Google Scholar : PubMed/NCBI
23	Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002. View Article : Google Scholar : PubMed/NCBI
24	Quintarelli C, Dotti G, Hasan ST, et al: High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 117:3353–3362. 2011. View Article : Google Scholar : PubMed/NCBI
25	Yan M, Himoudi N, Basu BP, et al: Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-aza-2′-deoxycytidine. Cancer Immunol Immunother. 60:1243–1255. 2011.PubMed/NCBI